Literature DB >> 16808908

Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.

Chen Xue1, Wang Lan-Lan, Cai Bei, Chen Jie, Feng Wei-Hua.   

Abstract

OBJECTIVES: To explore the relationships between Fas-FasL-mediated signaling pathway and apoptosis disturbance of T lymphocyte subset in patients with SLE.
METHODS: Flow cytometry was used to determine the percentage of apoptotic lymphocytes and necrotic lymphocytes by AnnexinV-FITC/PI double staining. Cell surface expression rates of Fas, FasL, and intracellular expression rates of activated caspase-3 were evaluated by two-color flow cytometry analysis in peripheral T lymphocyte subsets of SLE patients with inactive disease (n=22) and with active disease (n=17). The serum concentration of anti-nucleosome antibodies in SLE patients were assayed by ELISA immunoassay methods. Health volunteers (n=13) served as controls.
RESULTS: The percentage of early apoptotic cells was enhanced in patients with active disease (P=0.001, vs. control) and in patients with inactive disease (P=0.004, vs. control). Compared with health control, the percentage of necrotic cells was significant higher in patients with active disease (P=0.001). The percentages of CD4(+)T cells expressing Fas (P=0.023, vs. control) and FasL (P=0.001, vs. control) were increased in patients with active disease. But there were no obvious differences of expression rates of Fas and FasL on T cell subset between two disease groups (P>0.05). In patients with active disease the percentage of CD4(+)T cells or CD8(+)T cells expressing intracellular activated caspase-3 significantly increased compared to inactive disease patients (P=0.018, P=0.027, respectively) and health controls (P=0.001, P=0.001, respectively). The serum concentration of anti-nucleosome antibodies was strikingly higher in patients with active disease (P=0.002, vs. patients with inactive disease; P=0.001, vs. control, respectively), however, the serum concentration of anti-nucleosome antibodies was not obviously different between patients with inactive disease and health control group (P=0.473). The percentage of apoptotic cells correlated with the serum concentration of anti-nucleosome antibodies in SLE patients (r(s)=0.350, P=0.031).
CONCLUSIONS: Apoptosis of T lymphocyte subset in SLE patients increases. CD4(+)T cells are a state of active apoptosis. Fas/FasL-mediated apoptotic pathways are especially important for CD4(+)T cells undergoing apoptosis in SLE patients with active disease. Increased Fas expression results in a higher susceptibility to Fas-mediated apoptosis, which contributes to the increased levels of intracellular activated caspase-3 and accelerates apoptosis of T lymphocytes. The degree of lymphocytic apoptosis disturbance correlates with the level of anti-nucleosome antibodies in the circulation. Acceleration of lymphocytic apoptosis plays important roles in immune pathologic injury and immune regulation dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16808908     DOI: 10.1016/j.cellimm.2006.05.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  19 in total

1.  The pathway of estradiol-induced apoptosis in patients with systemic lupus erythematosus.

Authors:  Maryam Rastin; Mohammad Reza Hatef; Nafisseh Tabasi; Mahmoud Mahmoudi
Journal:  Clin Rheumatol       Date:  2011-08-12       Impact factor: 2.980

2.  [Total glucosides of paeony inhibits proliferation and promotes activation- induced cell death of mouse T cells in vitro].

Authors:  Chuanfeng Xiong; Jieying Qi; Rong Deng; Lifen Xie; Changzhang Li; Xiaoli Nie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

3.  Induction of PP2A Bβ, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus.

Authors:  José C Crispín; Sokratis A Apostolidis; Melissa I Finnell; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

Review 4.  Interaction between glutathione and apoptosis in systemic lupus erythematosus.

Authors:  Dilip Shah; Sangita Sah; Swapan K Nath
Journal:  Autoimmun Rev       Date:  2012-12-29       Impact factor: 9.754

5.  Incomplete Killing And Enhanced Activation of Islet-Reactive CD8+ T Cells by FasL-Expressing Dendritic Cells Limits Protection from Diabetes.

Authors:  Mikael Maksimow; Catharina Alam; Arno Hänninen
Journal:  Rev Diabet Stud       Date:  2008-11-10

6.  Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Authors:  David T Teachey; Alix E Seif; Valerie I Brown; Marlo Bruno; Ralph M Bunte; Yueh J Chang; John K Choi; Jonathan D Fish; Junior Hall; Gregor S Reid; Theresa Ryan; Cecilia Sheen; Patrick Zweidler-McKay; Stephan A Grupp
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

7.  Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis.

Authors:  Shihoko Okazaki; Fumihide Ogawa; Yohei Iwata; Toshihide Hara; Eiji Muroi; Kazuhiro Komura; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Shinichi Sato
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

8.  Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort.

Authors:  Sergio Durán; Mandar Apte; Graciela S Alarcón; Miranda C Marion; Jeffrey C Edberg; Robert P Kimberly; Jie Zhang; Carl D Langefeld; Luis M Vilá; John D Reveille
Journal:  Arthritis Rheum       Date:  2008-09-15

9.  Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus: relation to the organ damage and lymphocytes apoptosis.

Authors:  Lian-Hong Li; Wen-Xian Li; Ou Wu; Guo-Qing Zhang; Hai-Feng Pan; Xiang-Pei Li; Jian-Hua Xu; Hong Dai; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2008-11-20       Impact factor: 2.316

Review 10.  Systemic lupus erythematosus: new molecular targets.

Authors:  José C Crispín; Vasileios Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.